SGLT-2 inhibitors, as multifunctional drugs, have demonstrated exceptional renal and cardiovascular protective effects in the treatment of non-diabetic CKD, significantly expanding their clinical application and value. This evidence concerns the gene SLC5A2 and chronic kidney disease.